The renin-angiotensin system: new horizons.

摘要

The development of the first peptide angiotensin-con-verting enzyme inhibitor in the 1970s [1] represents a major milestone in the history of the treatment of hypertension. Since this time, the renin-angiotensin system (RAS) has become a cornerstone in strategies to treat hypertension and reduce cardiovascular risk clinically. However, cardiovascular disease remains a leading cause of death and disability worldwide; although major clinical trials have refined and changed treatment approaches over the last decade, significant advances have not been forthcoming. Effective preventive measures require a clearer understanding of the factors that initiate and 'set' long-term changes in arterial pressure control.